Ultra Select Medical Announces Merger with Platinum Healthcare

Ultra Select Medical is a privately owned and operated ultrasound company in the United States offering top manufacturers and brands in the industry with a cost-competitive edge.

Managing partners, W.C. Peeler, Mike Wilson, and Chris Munyon have been cornering the ultrasound system provider market for more than two decades. They pride themselves on their stock availability, comprehensive service contracts, and all-encompassing ultrasound system services.

Ultra Select Medical not only handles the sales side of the industry; they also provide qualified repair and preventative maintenance, making them a one-stop shop for your ultrasound system needs. They participate regularly in research with the intent to ensure that ultrasound systems are continually improving so patients around the globe can benefit from their advanced diagnostic capabilities and quality.

Peeler, Wilson, and Munyon are excited to announce that Ultra Select Medical and Platinum Healthcare will soon be combining operations. They believe that bringing Platinum into the fold will take their company to new heights and help in their desire to be a clear choice for ultrasound systems and services for a global audience.

Platinum Healthcare is currently a leader in the ultrasound industry, being an authorized distributor for Siemens Medical. They are committed to delivering cutting-edge technology that is designed to improve physician and customer experiences in clinical care centers around the nation. Platinum provides warranty coverage and 24/7 hour support after installation to ensure you receive the highest quality systems and support.

“Combining with the Ultra Select team will enable us to continue to grow our installed base and provide exceptional support to our new and existing customers. We are excited about the combined entity and look forward to continuing our place as one of the premier providers of ultrasound systems to the private sector in the U.S.” – Howard Taroff (President, Platinum Healthcare)

“We believe that the merger will help us to provide the most comprehensive, convenient, cutting-edge, and innovative ultrasound system offerings in the industry. We are looking forward to moving on to the next chapter of our company’s growth endeavors with Platinum at our side.”  – W.C. Peeler

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”